A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Study Participants with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Study of PBCAR20A in Participants with Relapsed/Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Sponsor: Precision BioSciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS9514
U.S. Govt. ID: NCT04030195
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR20A to treat certain types of cancers. PBCAR20A is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR20A came from healthy people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with leukemia or lymphoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator